Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
- None.
- None.
Insights
The reported financial performance of Revance Therapeutics showcases significant growth, with a 28% and 80% year-over-year increase in quarterly and annual product revenues, respectively. The company's guidance of at least $280 million for 2024 suggests confidence in the continued demand for its aesthetic products, particularly DAXXIFY®. This forecast positions DAXXIFY as a potential blockbuster, indicating expected widespread market acceptance and substantial revenue generation. The financial discipline is further evidenced by operating expenses (OPEX) aligning with the lower end of the guidance range, which may be viewed favorably by investors seeking efficient cost management.
Furthermore, the achievement of a permanent J-Code for DAXXIFY in January 2024 simplifies the reimbursement process for providers, potentially increasing the product's market penetration. However, the company's net loss indicates ongoing investments in sales, marketing and R&D, which are common for companies in growth phases. Investors should monitor the cash reserves, which currently stand at $253.9 million, to ensure the company can sustain its operations and investment plans until it anticipates reaching positive Adjusted EBITDA in 2025.
Revance's strategic focus on the U.S. aesthetics market is evident in the strong performance of the RHA Collection and DAXXIFY. With DAXXIFY's volume increasing by 22% over the previous quarter and the majority of revenue coming from reordering accounts, there is clear evidence of customer satisfaction and product loyalty. This is a positive indicator for future sales stability and growth. The RHA Collection's designation as the fastest-growing filler in the market reflects successful product differentiation and market penetration strategies.
It's important to note that the aesthetics market is highly competitive, with consumer preferences and technological advancements playing significant roles in shaping market dynamics. Revance's entry into the therapeutics market with DAXXIFY for cervical dystonia, expected mid-year, diversifies its portfolio and may reduce reliance on the aesthetics segment. This move could open additional revenue streams and mitigate risks associated with market saturation or shifts in consumer trends in the aesthetics industry.
The commercial launch of DAXXIFY for cervical dystonia represents a strategic expansion into therapeutic applications, which could enhance the company's growth trajectory and market share. Cervical dystonia is a neurological condition that causes abnormal muscle contractions and treatments in this space are highly valued for their impact on patient quality of life. The introduction of DAXXIFY into this market not only diversifies Revance's product offerings but also caters to an area with significant unmet medical needs.
From a research and development perspective, the reported decrease in R&D expenses, due to capitalization of manufacturing-related expenses and an employee retention credit, suggests a maturation of product development. However, investors should be aware that R&D investments are crucial for long-term sustainability in the biotech sector. The balance between managing expenditures and investing in future product pipelines will be critical to Revance's success as it continues to innovate and expand its market presence.
– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of
– Q4 DAXXIFY volume up
– 2024 product revenue guidance of at least
– DAXXIFY for cervical dystonia on track for commercial launch mid-year; Permanent J-Code for DAXXIFY received January 2024.
– 2023 GAAP and non-GAAP OPEX on the low end of previously announced guidance ranges; 2024 GAAP and non-GAAP OPEX guidance of
– Cash, cash equivalents and short-term investments of
– Conference call and webcast today at 4:30 p.m. ET.
Financial Highlights
-
Total revenue for the fourth quarter 2023 was
$69.8 million $49.9 million 40% increase, primarily due to increased sales of DAXXIFY. Total revenue for the full year 2023 was$234.0 million $132.6 million 77% increase, primarily due to increased sales of the RHA Collection and DAXXIFY. Total revenue for the fourth quarter included$58.5 million $34.5 million $24.0 million $2.3 million $9.1 million
-
Selling, general and administrative (SG&A) expenses for the fourth quarter and full year ended December 31, 2023 were
$85.2 million $297.7 million $65.2 million $223.9 million U.S. generally accepted accounting principles (“GAAP”). Excluding depreciation, amortization, stock-based compensation and restructuring charges, non-GAAP SG&A expenses were$76.5 million $253.4 million
-
Research and development (R&D) expenses for the fourth quarter and full year ended December 31, 2023 were
$20.4 million $79.4 million $19.5 million $101.3 million $18.6 million $65.5 million
-
Total operating expenses (OPEX) for the fourth quarter and full year ended December 31, 2023 were
$123.8 million $550.8 million $194.3 million $474.5 million $95.2 million $318.9 million $545 million $585 million $315 million $335 million
-
Net loss for the fourth quarter and full year ended December 31, 2023 was
$55.7 million $324.0 million $146.0 million $356.4 million $42.6 million $160.1 million $47.2 million $188.3 million
-
Cash, cash equivalents and short-term investments as of December 31, 2023 were
$253.9 million
“With the continued growth of DAXXIFY and the RHA Collection and our launch into the therapeutics market this year, we are well positioned to execute on our strategic priorities and achieve our product revenue guidance of at least
Foley continued, “In therapeutics, we are excited to realize another key milestone in the launch of DAXXIFY for cervical dystonia. We received our J-Code in early January and have already achieved greater than
Fourth Quarter Highlights and Subsequent Updates
Aesthetics
-
Sequential growth in DAXXIFY adoption in the first five quarters of market introduction, generating
$95.0 million
-
Fourth quarter and full year 2023 DAXXIFY revenue of
$24.0 million $84.0 million 22% over the third quarter, with revenue offset by a lower average selling price resulting from the new DAXXIFY pricing strategy. Revenue from reordering accounts represented more than two-thirds of total DAXXIFY revenue in the fourth quarter and the company ended the year with over 3,000 accounts that have ordered DAXXIFY.
-
RHA Collection continues to be the fastest-growing filler by market share out of the six brands on the U.S. market. Fourth quarter and full year 2023 RHA Collection revenue of
$34.5 million $128.6 million
-
In January 2024, the
U.S. Food and Drug Administration (FDA) approved the expansion of the label for RHA 3 to include injection into the vermillion body, vermillion border and oral commissure for lip augmentation and lip fullness in adults aged 22 years and older. RHA 3 was previously approved for the correction of moderate to severe dynamic wrinkles and folds, such as nasolabial folds. Revance anticipates launching the new indication in Q2 2024, further expanding the innovation and versatility of the RHA Collection.
- Accounts across Revance’s aesthetic portfolio totaled over 7,000 at the end of the fourth quarter 2023.
Therapeutics
-
Revance has already obtained DAXXIFY coverage for over 140 million commercial lives, which includes 25 of the 30 largest payers in the country, representing over
50% of commercial lives covered prior to commercial launch.
-
The DAXXIFY cervical dystonia (CD) PrevU program continues to advance. Since the program’s initiation in September 2023, more than 300 patients have been treated with DAXXIFY across approximately 30 practices, allowing Revance to collect valuable real-world clinical insights to help inform the commercial launch strategy and product positioning. Physicians continue to titrate doses across patient treatment cycles to optimize treatment outcomes. Approximately one-third of patients have completed their first treatment cycle and are now in their second treatment cycle. Feedback from physicians and patients on the product’s safety, efficacy and duration of treatment effect has been encouraging and in-line with the
ASPEN clinical program.
-
Based on a survey conducted by Revance in January, which included all 17 physicians who participated in the PrevU program at inception,
94% of participants indicated that they perceived DAXXIFY to last longer than what they have seen with conventional botulinum toxins, based on their treatment cycle 1 experience.
-
Revance is on track to launch DAXXIFY for the treatment of cervical dystonia in mid-year 2024, following the conclusion of the DAXXIFY CD PrevU program. Revance received its permanent J-Code for DAXXIFY in January 2024 from the
U.S. Centers for Medicare & Medicaid Services (CMS), which will streamline the reimbursement path for providers for DAXXIFY.
-
Revance announced the publication of its pivotal
ASPEN -1 study results in Neurology®, the medical journal of the American Academy of Neurology, reinforcing the long duration of effect and favorable safety profile of DAXXIFY for the treatment of cervical dystonia. The study results served as the basis for theU.S. FDA's approval of the indication in August 2023.
2024 Strategic Priorities
- Aesthetics: Grow DAXXIFY share by highlighting the value proposition of the product’s peptide formulation, long-duration, fast-onset and the appearance of improved skin quality; strengthen provider partnerships through robust engagement initiatives and thought leadership efforts; grow share of RHA Collection with continued training and education, indication expansion and realization of portfolio synergies.
-
Therapeutics: Successfully complete the DAXXIFY CD PrevU program; leverage learnings and real-world clinical insights to support commercial success; secure at least
50% commercial coverage by commercial launch, which has already been achieved as of the issuance of this press release; launch DAXXIFY for cervical dystonia mid-year 2024.
-
Focused and disciplined capital allocation: Drive top-line growth through focused investments in aesthetics and therapeutics while exercising disciplined expense management and capital allocation. Revance is on track to fully exit its OPUL® payments business by the end of Q1 2024, enabling greater focus on the company’s strategic priorities in aesthetics and therapeutics while generating up to approximately
$20 million
-
Enhanced and streamlined organizational structure: With the appointment of Erica Jordan as Chief Commercial Officer in the fourth quarter of 2023, the commercial organization was restructured to integrate and streamline marketing, sales, commercial operations, professional partnerships, strategy, data analytics and professional engagement functions. The new structure is designed to support the company’s strategic priorities by enhancing execution and performance while improving efficiencies.
Further, in connection with the previously announced departure of Dustin Sjuts, President of Revance, effective March 31, 2024, Mark Foley, Chief Executive Officer, will reassume responsibility for the company’s therapeutics business along with clinical, regulatory, quality, R&D and medical. Reporting to Mark across these functions is David Hollander, MD, MBA, Chief Medical Officer, who will take on the additional role of Global Therapeutics Franchise Lead. In this role, David will lead the company's global therapeutics strategy as well asU.S. commercial sales, marketing and payor functions. Tobin Schilke, Chief Financial Officer, will assume responsibility over the company’s manufacturing and supply chain operations.
2024 Guidance and Financial Outlook
-
Product revenue guidance: Revance expects 2024 total product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least
$280 million - RHA Collection DAXXIFY Aesthetic market share growth through deeper and broader account penetration.
- DAXXIFY cervical dystonia launch expected mid-year 2024 and related modest revenue contribution.
-
Operating expense guidance: Revance expects 2024 GAAP operating expenses to be between
$460 million $490 million $290 million $310 million 14% and6% reduction from the company's 2023 operating expenses. The reduction is driven primarily by the exit of the company's OPUL payments business, in addition to the streamlining of the organization and improved operating efficiencies. Revance expects non-GAAP selling, general and administrative (SG&A) expenses to be between$240 million $255 million
-
Financial outlook: With cash, cash equivalents, and short-term investments of
$253.9 million
Longer-term, the company reaffirms its blockbuster potential inU.S. aesthetics supported by its innovative product portfolio including DAXXIFY and the RHA Collection. The company expects to increase revenue growth through deeper and broader account penetration of DAXXIFY and RHA and the introduction of new RHA indications and products.
Further, the company believes meaningful upside can be achieved with the expansion of DAXXIFY into therapeutics and internationally, as well as the company’s strategic partnerships with Fosun and Viatris – representing at least$5.0 billion
Conference Call
Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on February 28, 2024, to discuss its financial results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for
A replay of the call will be available beginning February 28, 2024, at 4:30 p.m. PT / 7:30 p.m. ET to May 28, 2024 at 4:30 p.m. PT / 7:30 p.m. ET. To access the replay, please register through the webcast link found in the investor relations section of the company’s website. The webcast will be available in the investor relations section of the company's website for 90 days following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the
Revance’s global headquarters and experience center is located in
“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.
Forward-Looking Statements
Any statements in this press release that are not statements of historical fact, including statements related to our guidance, including 2024 revenue and operating, selling, general and administrative expense guidance and related guidance assumptions, anticipated product revenue and volume growth; our blockbuster potential; our expected cash flow breakeven; our ability and timing related to achieving positive Adjusted EBITDA; our ability to execute our strategic priorities; our capital requirements and capital allocation plans; our potential to strengthen relationships with healthcare providers; the impact of our pricing strategy on our results, customer support and DAXXIFY adoption; the timing and plans related to the launch of DAXXIFY for the treatment of cervical dystonia; the commercial success of DAXXIFY; the exit of the OPUL payments business and anticipated cost savings generated by the exit; international expansion; the RHA® Collection of dermal fillers, including products pipeline, the launch of new indications and our ability to capitalize on portfolio synergies; the growth potential of our products, business and the market; our ability to increase product adoption; the potential to set a new standard of care; the potential benefits of our products, including efficacy, duration, fast-onset, improvement in skin quality and safety; our strategic partnerships; the anticipated approvals of DAXXIFY and commercialization of DAXXIFY through our Fosun partnership; development of a biosimilar to onabotulinumtoxinA for injection with our partner, Viatris; and our business and marketing strategy, and timeline, goals, plans and prospects, including our commercialization plans; constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from our expectations. These risks and uncertainties relate to, but are not limited to: our ability to obtain funding for our operations; the timing of capital expenditures; the accuracy of our estimates regarding expenses, revenues, capital requirements, cost savings related to the divestiture of the OPUL payments business and supply chain and operational efficiencies; our financial performance and the economics of DAXXIFY and the RHA Collection of dermal fillers; the extent of future impairment charges; our ability to comply with our debt obligations; the impact of macroeconomic factors on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, regulatory meetings, inspections and approvals, clinical trials and other aspects of our business and on the market; our ability to maintain approval of our products; our ability and the ability of our partners to manufacture supplies for DAXXIFY and our drug product candidates; our ability to acquire supplies of the RHA Collection of dermal fillers; the uncertain clinical development process; our ability to obtain, and the timing relating to, regulatory submissions and approvals with respect to our drug product candidates and third-party manufacturers; the risk that clinical trials may not have an effective design or generate positive results or that positive results would assure regulatory approval or commercial success; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, safety, efficacy, duration, commercial acceptance, market, competition and/or size and growth potential of DAXXIFY, the RHA Collection of dermal fillers, and our drug product candidates, if approved; our ability to successfully commercialize DAXXIFY and to continue to successfully commercialize the RHA Collection of dermal fillers; the timing and cost of commercialization activities; securing or maintaining adequate coverage or reimbursement by third-party payers for DAXXIFY; the proper training and administration of our products by physicians and medical staff; our ability to maintain and gain acceptance from injectors and physicians in the use of DAXXIFY for aesthetic and therapeutic indications; our ability to strengthen professional partnerships; our ability to expand sales and marketing capabilities; the status of commercial collaborations; our ability to effectively manage the exit of the OPUL payments business; changes in and failures to comply with laws and regulations; our ability to continue obtaining and maintaining intellectual property protection for our products; the cost and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; our ability to limit or mitigate cybersecurity incidents; the volatility of our stock price; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risk Factors" in our Form 10-K expected to be filed with the SEC on February 28, 2024, and including, without limitation, our Form 10-Qs for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, filed with the SEC on May 9, 2023, August 8, 2023 and November 8, 2023, respectively. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Use of Non-GAAP Financial Measures
Revance has presented certain preliminary and unaudited non-GAAP financial measures and forward-looking non-GAAP financial measures in this release, including non-GAAP SG&A expenses, non-GAAP R&D expenses; non-GAAP OPEX; and Adjusted EBITDA. Non-GAAP SG&A expense and non-GAAP R&D expense exclude depreciation, amortization, stock-based compensation and restructuring charges; and non-GAAP OPEX excludes costs of revenue (exclusive of amortization), depreciation, amortization, stock-based compensation and restructuring and impairment charges. Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization, stock-based compensation and extraordinary items such as restructuring and impairment charges. The company excludes costs of revenue (exclusive of amortization), depreciation, amortization, stock-based compensation and extraordinary items like restructuring and impairment charges because management believes the exclusion of these items is helpful to investors to evaluate the Company’s recurring operational performance. Company management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an ongoing basis, and internally for operating, budgeting and financial planning purposes. The non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.
Revance is unable to reconcile forward-looking non-GAAP OPEX, non-GAAP SG&A expenses or Adjusted EBITDA to the most directly comparable GAAP measure because the items that are being excluded from the non-GAAP financial measure are difficult to predict and a reconciliation or a range of results could lead to disclosure that would be imprecise or potentially misleading. Material changes to any one of the exclusions could have a significant effect on our forward-looking estimates and GAAP results. Such items include costs of revenue (exclusive of amortization), depreciation, amortization and stock-based compensation, as well as extraordinary items like restructuring and impairment charges.
Sources
-
Includes
U.S. therapeutic market of$2.2 billion $2.7 billion $223 million $225 million
REVANCE THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) |
|||||||
|
December 31, |
||||||
|
2023 |
|
2022 |
||||
ASSETS |
|||||||
CURRENT ASSETS |
|
|
|
||||
Cash and cash equivalents |
$ |
137,329 |
|
|
$ |
108,965 |
|
Restricted cash, current |
|
550 |
|
|
|
— |
|
Short-term investments |
|
116,586 |
|
|
|
231,742 |
|
Accounts receivable, net |
|
27,676 |
|
|
|
11,339 |
|
Inventories |
|
45,579 |
|
|
|
18,325 |
|
Prepaid expenses and other current assets |
|
11,145 |
|
|
|
4,356 |
|
Total current assets |
|
338,865 |
|
|
|
374,727 |
|
Property and equipment, net |
|
17,225 |
|
|
|
13,799 |
|
Goodwill |
|
— |
|
|
|
77,175 |
|
Intangible assets, net |
|
9,808 |
|
|
|
35,344 |
|
Operating lease right-of-use assets |
|
53,167 |
|
|
|
39,223 |
|
Finance lease right-of-use asset |
|
19,815 |
|
|
|
6,393 |
|
Restricted cash, non-current |
|
6,870 |
|
|
|
6,052 |
|
Finance lease prepaid expense |
|
32,383 |
|
|
|
27,500 |
|
Other non-current assets |
|
321 |
|
|
|
1,687 |
|
TOTAL ASSETS |
$ |
478,454 |
|
|
$ |
581,900 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|||||||
CURRENT LIABILITIES |
|
|
|
||||
Accounts payable |
$ |
13,809 |
|
|
$ |
4,546 |
|
Accruals and other current liabilities |
|
53,824 |
|
|
|
59,357 |
|
Deferred revenue, current |
|
10,737 |
|
|
|
6,867 |
|
Finance lease liability, current |
|
2,651 |
|
|
|
669 |
|
Operating lease liabilities, current |
|
5,703 |
|
|
|
4,243 |
|
Debt, current |
|
2,500 |
|
|
|
— |
|
Total current liabilities |
|
89,224 |
|
|
|
75,682 |
|
Debt, non-current |
|
426,595 |
|
|
|
379,374 |
|
Deferred revenue, non-current |
|
70,419 |
|
|
|
78,577 |
|
Operating lease liabilities, non-current |
|
40,985 |
|
|
|
34,182 |
|
Other non-current liabilities |
|
2,835 |
|
|
|
1,485 |
|
TOTAL LIABILITIES |
|
630,058 |
|
|
|
569,300 |
|
STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
||||
Preferred stock, par value |
|
— |
|
|
|
— |
|
Common stock, par value |
|
88 |
|
|
|
82 |
|
Additional paid-in capital |
|
1,926,654 |
|
|
|
1,767,266 |
|
Accumulated other comprehensive gain (loss) |
|
14 |
|
|
|
(374 |
) |
Accumulated deficit |
|
(2,078,360 |
) |
|
|
(1,754,374 |
) |
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) |
|
(151,604 |
) |
|
|
12,600 |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
$ |
478,454 |
|
|
$ |
581,900 |
|
REVANCE THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) |
|||||||||||||||
|
|
|
|
||||||||||||
|
Quarter Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Product revenue |
$ |
58,498 |
|
|
$ |
45,730 |
|
|
$ |
212,658 |
|
|
$ |
118,131 |
|
Service revenue |
|
2,307 |
|
|
|
2,944 |
|
|
|
12,249 |
|
|
|
6,990 |
|
Collaboration revenue |
|
8,994 |
|
|
|
1,247 |
|
|
|
9,133 |
|
|
|
7,444 |
|
Total revenue |
|
69,799 |
|
|
|
49,921 |
|
|
|
234,040 |
|
|
|
132,565 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Cost of product revenue (exclusive of amortization) |
|
15,420 |
|
|
|
20,284 |
|
|
|
62,335 |
|
|
|
44,414 |
|
Cost of service revenue (exclusive of amortization) |
|
2,052 |
|
|
|
3,231 |
|
|
|
12,028 |
|
|
|
7,253 |
|
Selling, general and administrative |
|
85,243 |
|
|
|
65,237 |
|
|
|
297,732 |
|
|
|
223,934 |
|
Research and development |
|
20,366 |
|
|
|
19,541 |
|
|
|
79,410 |
|
|
|
101,286 |
|
Goodwill impairment |
|
— |
|
|
|
69,789 |
|
|
|
77,175 |
|
|
|
69,789 |
|
Intangible asset impairment |
|
— |
|
|
|
— |
|
|
|
16,007 |
|
|
|
— |
|
Amortization |
|
671 |
|
|
|
16,250 |
|
|
|
6,130 |
|
|
|
27,847 |
|
Total operating expenses |
|
123,752 |
|
|
|
194,332 |
|
|
|
550,817 |
|
|
|
474,523 |
|
Loss from operations |
|
(53,953 |
) |
|
|
(144,411 |
) |
|
|
(316,777 |
) |
|
|
(341,958 |
) |
Interest income |
|
3,434 |
|
|
|
3,031 |
|
|
|
13,285 |
|
|
|
4,891 |
|
Interest expense |
|
(5,398 |
) |
|
|
(3,752 |
) |
|
|
(19,356 |
) |
|
|
(16,474 |
) |
Other income (expense), net |
|
218 |
|
|
|
(820 |
) |
|
|
(838 |
) |
|
|
(2,181 |
) |
Loss before income taxes |
|
(55,699 |
) |
|
|
(145,952 |
) |
|
|
(323,686 |
) |
|
|
(355,722 |
) |
Income tax provision |
|
— |
|
|
|
— |
|
|
|
(300 |
) |
|
|
(700 |
) |
Net loss |
|
(55,699 |
) |
|
|
(145,952 |
) |
|
|
(323,986 |
) |
|
|
(356,422 |
) |
Unrealized gain (loss) |
|
27 |
|
|
|
86 |
|
|
|
388 |
|
|
|
(356 |
) |
Comprehensive loss |
$ |
(55,672 |
) |
|
$ |
(145,866 |
) |
|
$ |
(323,598 |
) |
|
$ |
(356,778 |
) |
Basic and diluted net loss |
$ |
(55,699 |
) |
|
$ |
(145,952 |
) |
|
$ |
(323,986 |
) |
|
$ |
(356,422 |
) |
Basic and diluted net loss per share |
$ |
(0.62 |
) |
|
$ |
(1.82 |
) |
|
$ |
(3.83 |
) |
|
$ |
(4.90 |
) |
Basic and diluted weighted-average number of shares used in computing net loss per share |
|
90,146,142 |
|
|
|
80,126,454 |
|
|
|
84,599,409 |
|
|
|
72,713,340 |
|
REVANCE THERAPEUTICS, INC.
Product Revenue Breakdown (Unaudited) |
|||||||||||
|
|
|
|
||||||||
|
Quarter Ended December 31, |
|
Year Ended December 31, |
||||||||
(in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||
Product: |
|
|
|
|
|
|
|
||||
RHA® Collection of dermal fillers |
$ |
34,467 |
|
$ |
34,755 |
|
$ |
128,647 |
|
$ |
107,156 |
DAXXIFY® |
|
24,031 |
|
|
10,975 |
|
|
84,011 |
|
|
10,975 |
Total product revenue |
$ |
58,498 |
|
$ |
45,730 |
|
$ |
212,658 |
|
$ |
118,131 |
Reconciliation of GAAP SG&A Expense to Non-GAAP SG&A Expense (Unaudited) |
|||||||||||||||
|
|
|
|
||||||||||||
|
Quarter Ended December 31, |
|
Year Ended December 31, |
||||||||||||
(in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
GAAP SG&A expense |
$ |
85,243 |
|
|
$ |
65,237 |
|
|
$ |
297,732 |
|
|
$ |
223,934 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation |
|
(7,772 |
) |
|
|
(8,658 |
) |
|
|
(38,814 |
) |
|
|
(36,595 |
) |
Depreciation and amortization |
|
(419 |
) |
|
|
(1,048 |
) |
|
|
(4,234 |
) |
|
|
(4,238 |
) |
Restructuring charges |
|
(528 |
) |
|
|
— |
|
|
|
(1,260 |
) |
|
|
— |
|
Non-GAAP SG&A expense |
$ |
76,524 |
|
|
$ |
55,531 |
|
|
$ |
253,424 |
|
|
$ |
183,101 |
|
Reconciliation of GAAP R&D Expense to Non-GAAP R&D Expense (Unaudited) |
|||||||||||||||
|
|
|
|
||||||||||||
|
Quarter Ended December 31, |
|
Year Ended December 31, |
||||||||||||
(in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
GAAP R&D expense |
$ |
20,366 |
|
|
$ |
19,541 |
|
|
$ |
79,410 |
|
|
$ |
101,286 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation |
|
(1,073 |
) |
|
|
(2,069 |
) |
|
|
(8,999 |
) |
|
|
(15,745 |
) |
Depreciation and amortization |
|
(329 |
) |
|
|
(168 |
) |
|
|
(3,329 |
) |
|
|
(1,647 |
) |
Restructuring charges |
|
(317 |
) |
|
|
— |
|
|
|
(1,610 |
) |
|
|
— |
|
Non-GAAP R&D expense |
$ |
18,647 |
|
|
$ |
17,304 |
|
|
$ |
65,472 |
|
|
$ |
83,894 |
|
Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) |
|||||||||||||||
|
Quarter Ended December 31, |
|
Year Ended December 31, |
||||||||||||
(in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
GAAP operating expenses |
$ |
123,752 |
|
|
$ |
194,332 |
|
|
$ |
550,817 |
|
|
$ |
474,523 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Goodwill and intangible asset impairment |
|
— |
|
|
|
(69,789 |
) |
|
|
(93,182 |
) |
|
|
(69,789 |
) |
Costs of revenue (exclusive of amortization) |
|
(17,472 |
) |
|
|
(23,515 |
) |
|
|
(74,363 |
) |
|
|
(51,667 |
) |
Stock-based compensation |
|
(8,845 |
) |
|
|
(10,727 |
) |
|
|
(47,813 |
) |
|
|
(52,340 |
) |
Depreciation and amortization |
|
(1,419 |
) |
|
|
(17,466 |
) |
|
|
(13,693 |
) |
|
|
(33,732 |
) |
Restructuring charges |
|
(845 |
) |
|
|
— |
|
|
|
(2,870 |
) |
|
|
— |
|
Non-GAAP operating expenses |
$ |
95,171 |
|
|
$ |
72,835 |
|
|
$ |
318,896 |
|
|
$ |
266,995 |
|
REVANCE THERAPEUTICS, INC.
Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) |
|||||||||||||||
|
Quarter Ended December 31, |
|
Year Ended December 31, |
||||||||||||
(in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Net loss |
$ |
(55,699 |
) |
|
$ |
(145,952 |
) |
|
$ |
(323,986 |
) |
|
$ |
(356,422 |
) |
Adjustments: |
|
|
|
|
|
|
|
||||||||
Goodwill and intangible asset impairment |
|
— |
|
|
|
69,789 |
|
|
|
93,182 |
|
|
|
69,789 |
|
Restructuring charges |
|
845 |
|
|
|
— |
|
|
|
2,870 |
|
|
|
— |
|
Stock-based compensation |
|
8,845 |
|
|
|
10,727 |
|
|
|
47,813 |
|
|
|
52,340 |
|
Interest expense, net |
|
1,964 |
|
|
|
721 |
|
|
|
6,071 |
|
|
|
11,583 |
|
Income tax provision |
|
— |
|
|
|
— |
|
|
|
300 |
|
|
|
700 |
|
Depreciation and amortization |
|
1,419 |
|
|
|
17,466 |
|
|
|
13,693 |
|
|
|
33,732 |
|
Adjusted EBITDA |
$ |
(42,626 |
) |
|
$ |
(47,249 |
) |
|
$ |
(160,057 |
) |
|
$ |
(188,278 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228178842/en/
Investors
Revance Therapeutics, Inc.:
Jessica Serra, 510-279-6886
jessica.serra@revance.com
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com
Media
Revance Therapeutics, Inc.:
Cathryn Castaldo, 615-245-7567
cathryn.castaldo@revance.com
Source: Revance Therapeutics, Inc.
FAQ
What were Revance Therapeutics' (RVNC) Q4 and full year 2023 product revenue figures?
What was the YoY growth percentage in revenue for Revance Therapeutics (RVNC) in Q4 and full year 2023?
What is Revance Therapeutics' (RVNC) 2024 product revenue guidance?
When is DAXXIFY for cervical dystonia expected to launch commercially?
What is Revance Therapeutics' (RVNC) cash position as of December 31, 2023?
